Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN | P07948 | 2/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | HCK | P08631 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.50 |
| ▸ | BCR | P11274 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | BRAF | P15056 | 9/20 | 0.48 |
| ▸ | CSF1R | P07333 | 7/20 | 0.48 |
| ▸ | RAF1 | P04049 | 5/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878749 | 0.92 | LYN (0.53) | LYNINSRLCKHCKSRC | |
| SCHEMBL13878736 | 0.92 | LYN (0.54) | LYNINSRLCKHCKSRC | |
| SCHEMBL13878745 | 0.91 | ABL1 (0.61) | LYNINSRLCKHCKSRC | |
| SCHEMBL1704685 | 0.90 | RAF1 (0.54) | LYNINSRLCKHCKSRC | |
| SCHEMBL13878744 | 0.88 | BRAF (0.61) | LYNINSRLCKHCKSRC | |
| SCHEMBL13878748 | 0.87 | LYN (0.48) | LYNINSRLCKHCKSRC | |
| SCHEMBL13878805 | 0.86 | LYN (0.55) | LYNINSRLCKHCKSRC | |
| SCHEMBL13878752 | 0.86 | CSF1R (0.57) | LYNLCKHCKSRCKDR | |
| SCHEMBL13878787 | 0.85 | BRAF (0.54) | LYNINSRLCKHCKSRC | |
| SCHEMBL13878750 | 0.84 | ABL1 (0.56) | LYNINSRLCKHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | LYN 40/4885INSR 1466/4885LCK 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.